What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

Envoy Medical Secures $30 Million Financing to Advance Fully Implanted Hearing Solutions

Envoy Medical Inc. (NASDAQ: COCH) has successfully closed a $30 million upsized financing round, marking a significant milestone for the medical technology company. The funding round was led by Nantahala Capital and billionaire shareholder Glen Taylor, with an additional $48 million potentially available through milestone warrants. This capital injection is designed to provide the company with a financial runway extending through the commercialization phase of its fully implanted hearing devices. Furthermore, the company reported positive progress in its clinical trials, reinforcing investor confidence in its technological pipeline. The successful financing reduces liquidity risks and positions Envoy Medical to transition from development to market entry. This move underscores the company's commitment to delivering advanced medical solutions to patients worldwide.

Envoy Medical Secures $30 Million Financing to Advance Fully Implanted Hearing Solutions

Instruments